Cartesian Therapeutics Inc.
$ 7.04
1.88%
06 Jan - close price
- Market Cap 183,065,000 USD
- Current Price $ 7.04
- High / Low $ 7.05 / 6.70
- Stock P/E N/A
- Book Value -1.38
- EPS -1.33
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -70.29 %
- 52 Week High 20.12
- 52 Week Low 5.98
About
Cartesian Therapeutics Inc. (ticker: RNAC), based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical leader specializing in nanoparticle immunomodulatory therapeutics designed to enhance immune responses across various therapeutic fields. Utilizing its cutting-edge drug platform, the company is focused on addressing critical unmet medical needs and is advancing a promising pipeline of biotherapeutics currently in clinical evaluation. With its commitment to innovation and patient care, Cartesian Therapeutics is well-positioned to significantly impact the biopharmaceutical landscape, particularly in the realm of immune-mediated therapies.
Analyst Target Price
$35.29
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-14 | 2025-05-08 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-07 | 2023-11-13 | 2023-08-17 | 2023-05-04 | 2023-03-02 |
| Reported EPS | -1.38 | -0.7724 | -0.65 | -0.5935 | -0.42 | 0.64 | -0.8 | -0.07 | -0.06 | -0.07 | -0.14 | 0.04 |
| Estimated EPS | -0.9 | -0.82 | -0.71 | -0.8257 | -0.55 | -0.09 | -1.42 | -0.04 | -0.06 | -0.08 | -0.09 | -0.07 |
| Surprise | -0.48 | 0.0476 | 0.06 | 0.2322 | 0.13 | 0.73 | 0.62 | -0.03 | 0 | 0.01 | -0.05 | 0.11 |
| Surprise Percentage | -53.3333% | 5.8049% | 8.4507% | 28.1216% | 23.6364% | 811.1111% | 43.662% | -75% | 0% | 12.5% | -55.5556% | 157.1429% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNAC
2026-01-06 12:09:24
Cartesian Therapeutics, Inc. announced new employment inducement grants to two employees on January 2, 2026. These grants consist of options to purchase 7,350 shares of the company's common stock at an exercise price of $6.76, vesting over four years. The awards were approved by the board under the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan to attract new talent.
2025-12-19 13:09:50
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has appointed Adrian Bot, M.D., Ph.D., to its Board of Directors. Dr. Bot brings extensive experience in immune, cell, gene therapy, and nanomedicines, having previously held leadership roles at Capstan Therapeutics and Kite Pharma, where he contributed to CAR T cell therapy development. His expertise is expected to be invaluable as Cartesian advances its pipeline in autoimmune diseases, particularly with its lead asset, Descartes-08.
2025-12-19 05:11:48
Cartesian Therapeutics, Inc. has announced the appointment of Adrian Bot, M.D., Ph.D., to its Board of Directors. Dr. Bot brings three decades of experience in biopharma R&D, particularly in immune, cell, gene therapy, and nanomedicines, and will serve on the Science and Technology Committee. The company anticipates his expertise will be crucial as they advance their pipeline and explore new opportunities in cell therapy for autoimmune diseases.
2025-12-18 21:11:48
Cartesian Therapeutics has appointed Adrian Bot, M.D., Ph.D., to its Board of Directors, where he will serve on the Science and Technology Committee. Dr. Bot brings extensive biopharma experience, particularly in immune, cell, gene therapy, and RNA-based precision medicines, having previously held leadership roles at Capstan Therapeutics and Kite Pharma. His expertise is expected to be invaluable as Cartesian advances its pipeline in cell therapy for autoimmune diseases.
2025-12-18 16:05:00
Cartesian Therapeutics has appointed Adrian Bot, M.D., Ph.D., to its Board of Directors, where he will serve on the Science and Technology Committee. Dr. Bot brings extensive experience in immune, cell, gene therapy, and nanomedicines, including pioneering work in CAR T cell therapies and RNA-based precision medicines. This appointment is expected to provide valuable insights as the company advances its pipeline in autoimmune diseases.
2025-12-17 13:09:10
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.00 despite recent downgrades from some firms. The company's shares were trading down approximately 7.6% after missing quarterly EPS estimates and reporting a loss of $(1.38) per share against an expected $(0.81). Cartesian Therapeutics, a clinical-stage biotech developing an mRNA CAR-T therapy, has a market capitalization of $215.5 million and institutional investors own 86.95% of its stock.
